Galectin Therapeutics (GALT) Equity Income (2014)
Galectin Therapeutics' quarterly Equity Income came in at -$10000.0 in Q4 2014, up 81.13% quarter-over-quarter from -$53000.0 in Q3 2014.
Galectin Therapeutics has reported Equity Income for 1 years, with the latest figure at -$10000.0 in Q4 2014.
- For the quarter ending Q4 2014, Equity Income changed N/A year-over-year to -$10000.0; the trailing twelve-month figure through Dec 2014 stood at -$400000.0 (changed N/A YoY), and the FY2014 full-year result was -$400000.0, changed N/A from the prior year.
- Equity Income for Q4 2014 stood at -$10000.0, up from -$53000.0 in the prior quarter.
- The five-year high for Equity Income was -$10000.0 in Q4 2014, with the low at -$270000.0 in Q1 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -10,000.00 |
| Sep 30, 2014 | -53,000.00 |
| Jun 30, 2014 | -67,000.00 |
| Mar 31, 2014 | -270,000.00 |